IMMURON LTD-SPON ADR (IMRN:NASDAQ)
$1.14 0.02 (1.7857%)
Analysed IMMURON LTD-SPON ADR (IMRN:NASDAQ) News Sources
Immuron (IMRN) Struggles After Announcing Trial Results
15-12-2025
yahoo.com
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
22-01-2026
yahoo.com
Immuron Reports HY26 Results and Strategic Reset
25-02-2026
yahoo.com
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
20-07-2026
yahoo.com
Immuron Double Digit 3Q Sales Growth
17-04-2026
yahoo.com
Emerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
22-04-2026
yahoo.com
Presenting on Emerging Growth Conference 92 Day 2 on May 7; Register to live stream
06-05-2026
yahoo.com
Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
06-07-2026
yahoo.com
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
16-07-2026
yahoo.com
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream
18-08-2026
yahoo.com
What is the current price of IMMURON LTD-SPON ADR (IMRN:NASDAQ)?
The current price of IMMURON LTD-SPON ADR (IMRN:NASDAQ) is $1.14.
IMMURON LTD-SPON ADR (IMRN:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMURON LTD-SPON ADR (IMRN:NASDAQ) since the previous trading day is $0.02.
IMMURON LTD-SPON ADR (IMRN:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMURON LTD-SPON ADR (IMRN:NASDAQ) since the previous trading day is 1.7857%.
What is the most recent average sentiment score for IMMURON LTD-SPON ADR (IMRN:NASDAQ)?
The most recent average sentiment score for IMMURON LTD-SPON ADR (IMRN:NASDAQ) is 64 out of 100.
What is the most recent average sentiment for IMMURON LTD-SPON ADR (IMRN:NASDAQ)?
The most recent sentiment for IMMURON LTD-SPON ADR (IMRN:NASDAQ) is .
SEC-8K** Filing Available For IMMURON LTD-SPON ADR (IMRN:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.